Alpha-Mannosidosis
Conditions
Brief summary
The overall objective is to evaluate the long-term efficacy of Lamazym i.v. treatment in patients with alpha-Mannosidosis previously enrolled in Lamazym trials and currently receiving the treatment according to the AfterCare Program.
Detailed description
The primary objective of the trial is to evaluate the impact of the long-term treatment with Lamazym upon the level of biomarker oligosaccharides in serum and upon the endurance as measured by the change from baseline in the number of steps climbed in 3 minutes (3MSCT). As secondary objectives, the long term efficacy of Lamazym will be investigated upon endurance as measured by the change from baseline in the number of meters walked in six minutes (6MWT), upon pulmonary function, motor proficiency by BOT-2 and hearing capability by audiometry. In addition, cognitive development will be assessed by Leiter-R test. CNS involvement will be evaluated with MRI/MRS (for patients who previously participated in rhLAMAN-02 trial), CSF biomarkers (Tau, NFL, GFAp) and CSF biomarkers oligosaccharides. Clearance of oligosaccharides in urine will be measured. Long-term safety and Pharmaco-Kinetic (PK) profile after long-term treatment as measured by rhLAMAN levels in plasma will be assessed as well. Quality of life will be assessed by questionnaires (CHAQ and EQ-5D-5L).
Interventions
DRUGLamazym
recombinant human alpha-mannosidase
Sponsors
Zymenex A/S
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. The subject must have participated in the phase 1 trial (EudraCT number: 2010-022084-36), phase 2a trial (EudraCT number: 2010-022085-26), phase 2b trial (EudraCT number: 2011-004355-40) or phase 3 trial (EudraCT number: 2012-000979-17) 2. The subject must still be receiving weekly intravenous infusions of Lamazym according to the AfterCare Program 3. The Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trial-related activities 4. The subject and his/her guardian(s) must have the ability to comply with the protocol
Exclusion criteria
1. History of bone marrow transplantation 2. Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial. Subjects unable to perform the motor tests independently from support are permitted to participate in the trial and will be evaluated for the remnant non motor endpoints 3. Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial 4. Pregnant and/or lactating women cannot participate in the trial. Concerning women of child bearing potential (WOCBP), the investigators will decide whether or not there is a need for contraception. This assessment will be done through interviews with the patient and parents. 5. Participation in other interventional trials testing IMP, including rhLAMAN-07 (EudraCT number: 2013-000336-97) and rhLAMAN-09 (EudraCT number: 2013-000321-31) trials with Lamazym 6. Pause of the IMP for 2 consecutive weeks during the last month. Subjects are allowed to be re-screened
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in reduction of oligosaccharides in serum | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Primary Endpoint evaluation as change |
| Change from baseline in 3 Minutes Stair Climb Test (3MSCT) | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Primary Endpoint evaluation as change |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pure Tone Audiometry (PTA) | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Endpoint evaluation as change |
| Assessment of mannose-rich oligosaccharides in brain tissue as measured by Magnetic Resonance Imaging (MRI) diffusion coefficient (for patients who previously participated in rhLAMAN-02) | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Endpoint evaluation as change |
| Cerebrospinal fluid biomarkers: Oligosaccharides in Cerebrospinal Fluid (CSF) | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Endpoint evaluation as change |
| Cerebrospinal fluid neuro-degeneration biomarkers: Tau Protein (Tau) in Cerebrospinal Fluid (CSF) | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Endpoint evaluation as change |
| Cerebrospinal fluid neuro-degeneration biomarkers: Neurofilament Protein Light (NFL) in Cerebrospinal Fluid (CSF) | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Endpoint evaluation as change |
| Cerebrospinal fluid neuro-degeneration biomarkers: Glial Fibrillary Acidic protein (GFAp) in Cerebrospinal Fluid (CSF) | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Endpoint evaluation as change |
| Drug exposure by Pharmaco Kinetic (PK) sampling profile on plasma | 1 week | Evaluation of steady state Pharmaco Kinetics |
| Measurement of in vivo biological activity of Lamazym in blood before and after Infusion of Lamazym | 1 week | Comparing with Anti Body (AB) and PK measurements. Measuring unit is mU/mL |
| Oligosaccharides in urine | 1 week | Evaluation of steady state |
| 6 Minute Walk Test (6MWT) | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Endpoint evaluation as change |
| Pulmonary function: Forced Vital Capacity (FVC) | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Endpoint evaluation as change |
| Pulmonary function: Forced Expiratory Volume during first second (FEV1) | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Endpoint evaluation as change |
| Pulmonary function: Peak Expiratory Flow Rate (PEF) | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Endpoint evaluation as change |
| Functional capacity according to Bruininks-Oseretsky test of Motor Proficiency (BOT-2) | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Endpoint evaluation as change |
| Equivalence age measured by Leiter International Performance Scale-Revised (Leiter-R) | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Endpoint evaluation as change |
| Assessment of mannose-rich oligosaccharides in brain tissue as measured by Magnetic Resonance Spectroscopy (MRS) visual score (for patients who previously participated in rhLAMAN-02) | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | Endpoint evaluation as change |
Other
| Measure | Time frame | Description |
|---|---|---|
| Development of clinically significant changes in the clinical laboratory Parameters: Hematology | 1 week | Safety endpoint assessed throughout the trial |
| Development of clinically significant changes in the clinical laboratory Parameters: Biochemistry | 1 week | Safety endpoint assessed throughout the trial |
| Development of clinically significant changes in the clinical laboratory Parameters: Urinalysis | 1 week | Safety endpoint assessed throughout the trial |
| Development of rhLAMAN antibodies | 1 week | Safety endpoint assessed throughout the trial |
| Development of rhLAMAN neutralizing/inhibitory antibodies | 1 week | Safety endpoint assessed throughout the trial |
| Development of clinically significant changes in vital signs and change in physical examination | 1 week | Safety endpoint assessed throughout the trial |
| Development of adverse events | 1 week | Safety endpoint assessed from signing of the Informed Consent Form (ICF) |
| Quality of life based on questionnaires | Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment | filled by the subject's guardian, will be evaluated by Childhood Health Assessment Questionnaire (CHAQ) questionnaires filled in by the subject's guardian, will be evaluated by CHAQ and EQ-5D-5L |
Countries
Denmark
Outcome results
None listed